Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. / (Record no. 1174)

MARC details
000 -LEADER
fixed length control field 04342naa a22006497i 4500
001 - CONTROL NUMBER
control field UMUN-OA-20261005-MLS-032
003 - CONTROL NUMBER IDENTIFIER
control field local
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20261005174904.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr||||||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 261005s2023 xx o u000 0 eng d
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1186/s12967-023-04292-3
Source of number or code doi
035 ## - SYSTEM CONTROL NUMBER
System control number (local)EuropePMC:PMC10327392
040 ## - CATALOGING SOURCE
Original cataloging agency local
Language of cataloging eng
Transcribing agency local
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title eng
100 0# - MAIN ENTRY--PERSONAL NAME
Personal name Gunjan Dagar
Relator term author.
245 10 - TITLE STATEMENT
Title Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. /
Statement of responsibility, etc. Gunjan Dagar; Ashna Gupta; Tariq Masoodi [and others].
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture [Place of publication not identified] :
Name of producer, publisher, distributor, manufacturer BMC,
Date of production, publication, distribution, manufacture, or copyright notice 2023.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (1 article).
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
500 ## - GENERAL NOTE
General note The source lists 17 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest.
500 ## - GENERAL NOTE
General note Publication type: Review article.
500 ## - GENERAL NOTE
General note Linked open-access copy: published version.
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open access; no subscription required for the linked open-access version.
Standardized terminology for access restriction Unrestricted online access
Source of term star
520 3# - SUMMARY, ETC.
Summary, etc. Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons Attribution. See the linked licence for the applicable terms.
Uniform Resource Identifier <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>
546 ## - LANGUAGE NOTE
Language note In English.
588 0# - SOURCE OF DESCRIPTION NOTE
Source of description note Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 ## - LOCAL NOTE (RLIN)
Local note Course allocation: B. Sc. Medical Laboratory Science.
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Tumor antigens
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunotherapy
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Hematological malignancy
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Solid tumor
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cytokine Release Syndrome
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antigen Escape
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term B. Sc. Medical Laboratory Science
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term UMUN open access collection
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term hematology
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Review articles.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Ashna Gupta
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Tariq Masoodi
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Sabah Nisar
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Maysaloun Merhi
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Sheema Hashem
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Ravi Chauhan
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Manisha Dagar
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Sameer Mirza
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Puneet Bagga
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Rakesh Kumar
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Ammira S Al-Shabeeb Akil
Relator term author.
773 0# - HOST ITEM ENTRY
Title Journal of translational medicine
Related parts Vol. 21, no. 1, (2023), pages/article 449
International Standard Serial Number 1479-5876
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://europepmc.org/articles/PMC10327392">https://europepmc.org/articles/PMC10327392</a>
Link text Read open-access publication
Public note Open access.
Access status 0
884 ## - DESCRIPTION CONVERSION INFORMATION
Conversion process Course selection and automated MARC21 enrichment from Europe PMC metadata.
Conversion date 20261005
Identifier of source metadata https://europepmc.org/articles/PMC10327392
Conversion agency local
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Suppress in OPAC No

No items available.